Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. (Q45417687)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 April 2006

Language	Label	Description	Also known as
English	Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.	scientific article published on 17 April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. (English)

1 reference

Europe PubMed Central

14 December 2017

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

14 December 2017

John R. Mascola

3

object named as

John R Mascola

1 reference

Europe PubMed Central

14 December 2017

author name string

Shixia Wang

1

1 reference

Europe PubMed Central

14 December 2017

Ranajit Pal

2

1 reference

Europe PubMed Central

14 December 2017

Te-Hui W Chou

4

1 reference

Europe PubMed Central

14 December 2017

Innocent Mboudjeka

5

1 reference

Europe PubMed Central

14 December 2017

Siyuan Shen

6

1 reference

Europe PubMed Central

14 December 2017

Qin Liu

7

1 reference

Europe PubMed Central

14 December 2017

Stephen Whitney

8

1 reference

Europe PubMed Central

14 December 2017

Timothy Keen

9

1 reference

Europe PubMed Central

14 December 2017

B C Nair

10

1 reference

Europe PubMed Central

14 December 2017

V S Kalyanaraman

11

1 reference

Europe PubMed Central

14 December 2017

Philip Markham

12

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

17 April 2006

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

350

1 reference

Europe PubMed Central

14 December 2017

34-47

1 reference

Europe PubMed Central

14 December 2017

1

1 reference

Europe PubMed Central

14 December 2017

Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

HIV and SIV gp120 binding does not predict coreceptor function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Antibody vs. HIV in a clash of evolutionary titans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Diversity considerations in HIV-1 vaccine selection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Application of the polyvalent approach to HIV-1 vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

HIV-1: nature's master of disguise

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Urgently needed: a filter for the HIV-1 vaccine pipeline

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Neutralizing antibody responses to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Production of high-titer helper-free retroviruses by transient transfection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Antibody protection: passive immunization of neonates against oral AIDS virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Direct visualization of HIV-1 entry: mechanisms and role of cell surface receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Genetic characterization of incident HIV type 1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

Identification of CXCR4 domains that support coreceptor and chemokine receptor functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Simian immunodeficiency virus DNA vaccine trial in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2006.02.032

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45417687&oldid=1382285030"